Mosquito protein could hold key to therapeutics against flaviviruses
A study has shown the mosquito protein AEG12 inhibits flaviviruses, the family of viruses that cause yellow fever, dengue and Zika.
List view / Grid view
A study has shown the mosquito protein AEG12 inhibits flaviviruses, the family of viruses that cause yellow fever, dengue and Zika.
A liver-on-a-chip model has been developed to more fully represent the natural progression of NAFLD than previous models.
A new CRISPR gene therapy for chronic pain has been shown in mice to temporarily repress a gene involved in sensing pain.
RiboMinus Bacteria 2.0 Transcriptome Isolation Kits perform efficient transcriptome enrichment from total bacterial RNA. Improve your RNA extraction from bacteria today.
A year on from discovering COVID-19 we are starting to understand why some people suffer more severely after infection. Sadya Arnett discusses recent research into the interconnection between host inflammation and SARS-CoV-2.
A new study has revealed that immunoglobulin-M antibodies recognise microvesicles, which are critical for the progression of thrombosis.
See our guide on DNA purification methods. From organic extraction through automated high-throughput runs, these research solutions make sample preparation easy.
A team has developed a novel inhibitor that blocks a protein in cancer cells, making drug-resistant tumours respond to chemotherapy.
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.
A monoclonal antibody (mAb) cocktail, that targets sites on the Spike protein other than the E484K residue, can neutralise SARS-CoV-2.
Researchers have found that mutations in SARS-CoV-2 T cell epitopes enable the virus to evade the immune response of killer T cells.
Sequencing and transcriptome data on iPSCs has been used to identify correlations between genetic variants and expression patterns.
A team has discovered how enzymes control the formation of bioactive rubromycin-polyketides, which could be used to bioengineer new compounds.
A team has used two viruses to administer specific tumour components in mice with cancer to stimulate their immune system.